Immunomedics, Inc. IMMU shares rose 17.2% to $2.52 following the announcement of interim Phase 2 Results with sacituzumab govitecan in lung cancers. Share volume was 170,000, compared to an all-day average of 297,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in